|Mr. Kåre Schultz||Pres, CEO & Director||26.47M||N/A||1961|
|Mr. Michael McClellan||Exec. VP & CFO||2.25M||N/A||1971|
|Mr. Mark Sabag||Exec. VP of Global HR||2.12M||N/A||1971|
|Dr. Carlo de Notaristefani||Exec. VP of Global Operations||2.53M||N/A||1958|
|Dr. Hafrun Fridriksdottir||Exec. VP of Global R&D||2.75M||N/A||1962|
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Teva Pharmaceutical Industries Limited’s ISS Governance QualityScore as of June 25, 2019 is 4. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 7; Compensation: 7.